Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/zgen)
is investigating potential claims against the board of directors of
ZymoGenetics, Inc. (ZymoGenetics or the Company) (NASDAQ: ZGEN)
concerning possible breaches of fiduciary duty and other violations of
law related to the Companys efforts to sell ZymoGenetics to
Bristol-Myers Squibb Company.
Our investigation concerns possible breaches of fiduciary duty and other
violations of law related to approval of the transaction by Companys
board of directors; in particular, whether the Company undertook a fair
process to obtain fair consideration for all shareholders of
ZymoGenetics. For more information regarding our investigation, please
contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at
(877) 316-3218 or by email at rmaniskas@rmclasslaw.com
or visit: www.rmclasslaw.com/cases/zgen.
Under the terms of the announced tender offer, ZymoGenetics shareholders
will receive $9.75 in cash for each share of ZymoGenetics they own if
the tender offer is completed. The companies expect the tender offer to
close approximately thirty days after commencement of the tender offer
on or about September 9, 2010.
If you own shares of ZymoGenetics and would like to learn more about
these claims or if you wish to discuss these matters and have any
questions concerning this announcement or your rights, contact Richard
A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online,
visit: www.rmclasslaw.com/cases/zgen.
You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com.
For more information about class action cases in general, please visit
our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan and
Maniskas, LLP is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal
courts nationwide.

Source: Business Wire